Allarity Therapeutics, Inc. Gain (Loss) on Investments
Allarity Therapeutics, Inc. (ALLR) reported Gain (Loss) on Investments of -$115.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-08.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnInvestments · last filed 2024-03-08
- Allarity Therapeutics, Inc. gain (loss) on investments for the quarter ending 2022-12-31 was $0.00.
- Allarity Therapeutics, Inc. gain (loss) on investments for the quarter ending 2022-09-30 was -$45.00K.
- Allarity Therapeutics, Inc. gain (loss) on investments for the quarter ending 2022-06-30 was -$34.00K.
- Allarity Therapeutics, Inc. gain (loss) on investments for the quarter ending 2022-03-31 was -$36.00K.
- Allarity Therapeutics, Inc. gain (loss) on investments for fiscal 2022 was -$115.00K.
- Allarity Therapeutics, Inc. gain (loss) on investments for fiscal 2021 was -$495.00K, a 169.92% decline from fiscal 2020.
- Allarity Therapeutics, Inc. gain (loss) on investments for fiscal 2020 was $708.00K.
| Period end | Gain (Loss) on Investments 3 month | Gain (Loss) on Investments 3 month as first filed | Gain (Loss) on Investments 6 month | Gain (Loss) on Investments 9 month | Gain (Loss) on Investments 9 month as first filed | Gain (Loss) on Investments 12 month |
|---|---|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$45.00K derived: sum of 2 quarters · filed 2024-03-08 | -$79.00K derived: sum of 3 quarters · filed 2024-03-08 | -$115.00K 10-K · filed 2024-03-08 | ||
| 2022-09-30 | -$45.00K 10-Q · filed 2023-11-14 | -$79.00K derived: sum of 2 quarters · filed 2023-11-14 | -$115.00K 10-Q · filed 2023-11-14 | -$293.00K derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | -$34.00K 10-Q · filed 2023-08-14 | -$70.00K 10-Q · filed 2023-08-14 | -$248.00K derived: sum of 3 quarters · filed 2023-08-14 | -$385.00K derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | -$36.00K 10-Q · filed 2023-05-11 | -$214.00K derived: sum of 2 quarters · filed 2023-05-11 | -$351.00K derived: sum of 3 quarters · filed 2023-05-11 | -$418.00K derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | -$178.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | -$315.00K derived: sum of 2 quarters · filed 2023-03-13 | -$382.00K derived: sum of 3 quarters · filed 2023-03-13 | -$495.00K 10-K · filed 2023-03-13 | ||
| 2021-09-30 | -$137.00K 10-Q · filed 2022-11-14 | $137.00K 10-Q · filed 2021-11-23 | -$204.00K derived: sum of 2 quarters · filed 2022-11-14 | -$317.00K 10-Q · filed 2022-11-14 | $317.00K 10-Q · filed 2021-11-23 | -$263.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$67.00K 10-Q · filed 2022-10-07 | -$180.00K 10-Q · filed 2022-10-07 | -$126.00K derived: sum of 3 quarters · filed 2022-10-07 | $117.00K derived: sum of 4 quarters · filed 2022-10-07 | ||
| 2021-03-31 | -$113.00K 10-Q · filed 2022-05-27 | -$59.00K derived: sum of 2 quarters · filed 2022-05-27 | $184.00K derived: sum of 3 quarters · filed 2022-05-27 | |||
| 2020-12-31 | $54.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-05-17 | $297.00K derived: sum of 2 quarters · filed 2022-05-17 | $708.00K 10-K · filed 2022-05-17 | |||
| 2020-09-30 | $243.00K 10-Q/A · filed 2022-05-17 | -$243.00K 10-Q · filed 2021-11-23 | $654.00K 10-Q/A · filed 2022-05-17 | -$654.00K 10-Q · filed 2021-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |